These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19394405)

  • 1. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells.
    Yuan B; Sierks MR
    Neurosci Lett; 2009 Jul; 459(1):16-8. PubMed ID: 19394405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein.
    Zhou C; Emadi S; Sierks MR; Messer A
    Mol Ther; 2004 Dec; 10(6):1023-31. PubMed ID: 15564134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging.
    Opazo F; Krenz A; Heermann S; Schulz JB; Falkenburger BH
    J Neurochem; 2008 Jul; 106(2):529-40. PubMed ID: 18410502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
    Emadi S; Barkhordarian H; Wang MS; Schulz P; Sierks MR
    J Mol Biol; 2007 May; 368(4):1132-44. PubMed ID: 17391701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine epitope mapping of monoclonal antibodies specific to human alpha-synuclein.
    Choi JY; Park HJ; Seong YM; Choi EY; Min BR; Rhim H
    Neurosci Lett; 2006 Apr 10-17; 397(1-2):53-8. PubMed ID: 16380207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.
    Schnack C; Danzer KM; Hengerer B; Gillardon F
    Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity.
    Lynch SM; Zhou C; Messer A
    J Mol Biol; 2008 Mar; 377(1):136-47. PubMed ID: 18237741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended half-life upon binding of destabilized intrabodies allows specific detection of antigen in mammalian cells.
    Sibler AP; Courtête J; Muller CD; Zeder-Lutz G; Weiss E
    FEBS J; 2005 Jun; 272(11):2878-91. PubMed ID: 15943819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells.
    Wu F; Poon WS; Lu G; Wang A; Meng H; Feng L; Li Z; Liu S
    Brain Res; 2009 Oct; 1292():173-9. PubMed ID: 19646423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impairment of microtubule system increases alpha-synuclein aggregation and toxicity.
    Kim M; Jung W; Lee IH; Bhak G; Paik SR; Hahn JS
    Biochem Biophys Res Commun; 2008 Jan; 365(4):628-35. PubMed ID: 18022384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates.
    Nannenga BL; Zameer A; Sierks MR
    FEBS Lett; 2008 Feb; 582(4):517-22. PubMed ID: 18230361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases.
    Cardinale A; Biocca S
    Trends Mol Med; 2008 Sep; 14(9):373-80. PubMed ID: 18693139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
    Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
    Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.
    Lee HJ; Suk JE; Bae EJ; Lee JH; Paik SR; Lee SJ
    Int J Biochem Cell Biol; 2008; 40(9):1835-49. PubMed ID: 18291704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrabody applications in neurological disorders: progress and future prospects.
    Miller TW; Messer A
    Mol Ther; 2005 Sep; 12(3):394-401. PubMed ID: 15964243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular antibodies (intrabodies) and their therapeutic potential.
    Lo AS; Zhu Q; Marasco WA
    Handb Exp Pharmacol; 2008; (181):343-73. PubMed ID: 18071953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing antibody specificity to different protein morphologies by AFM.
    Wang MS; Zameer A; Emadi S; Sierks MR
    Langmuir; 2009 Jan; 25(2):912-8. PubMed ID: 19090748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of alpha-synuclein to mitochondria within midbrain of mice.
    Li WW; Yang R; Guo JC; Ren HM; Zha XL; Cheng JS; Cai DF
    Neuroreport; 2007 Oct; 18(15):1543-6. PubMed ID: 17885598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft.
    Park JY; Kim KS; Lee SB; Ryu JS; Chung KC; Choo YK; Jou I; Kim J; Park SM
    J Neurochem; 2009 Jul; 110(1):400-11. PubMed ID: 19457104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.